SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    DeVita VT, Canellos GP. The lymphomas. Semin Hematol 1999; 36: 8494.
  • 2
    Jotti G, Bonadonna G. Prognostic factors in Hodgkin's disease; implications for modern treatment. Anticancer Res 1988; 8: 74960.
  • 3
    Marshall WH Jr., Breiman RS, Harell GS, Glatstein E, Kaplan HS. Computed tomography of abdominal para-aortic lymph node disease: preliminary observation with a 6 second scanner. Am J Roentgenol 1977;128: 75964.
  • 4
    Karimjee S, Brada M, Husband J, McCready VR. A comparison of gallium-67 single photon emission computed tomography and computed tomography in mediastinal Hodgkin's disease. Eur J Cancer 1992; 28A: 18567.
  • 5
    Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15: 16317.
  • 6
    Bendini M, Zuiani C, Bazzocchi M, Dalpiaz G, Zaja F, Englaro E. Magnetic resonance imaging and Ga-67 scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. MAGMA 1996; 4: 21324.
  • 7
    Israel O, Front D, Lam M, Ben-Haim S, Kleinhaus U, Ben-Shachar M, et al. Gallium-67 imaging in monitoring lymphoma response to treatment. Cancer 1988; 61: 243943.
  • 8
    Kostakoglu L, Yeh SD, Portlock C, Heelan R, Yao TJ, Niedzwiecki D, et al. Validation of gallium-67 citrate single photon emission tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992; 33: 34550.
  • 9
    Setoain FJ, Pons F, Herranz R, Vidal-Sicart S, Lomena F, Ayuso C, et al. Ga-67 scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma. Nucl Med Commun 1997; 18: 40511.
  • 10
    Bogart JA, Chung CT, Mariados NF, Vermont AI, Lemke SM, Grethlein S, et al. The value of gallium imaging after therapy for Hodgkin's disease. Cancer 1998; 82: 7549.
  • 11
    Front D, Bar-Shalom R, Mor M, Haim N, Epelbaum R, Frenkel A, et al. Hodgkin's disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Radiology 1999; 210: 48791.
  • 12
    Bekerman C, Hoffer PB, Bitran JD. The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med 1984; 14: 296322.
  • 13
    Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[18F] fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 1116.
  • 14
    Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32: 12118.
  • 15
    Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 3438.
  • 16
    Moog F, Bangerter M, Diederichs CG, Guhlman A, Kotzerke J, Merkle E, et al. Lymphoma: role of whole body 2-deoxy-2 [F-18] fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795800.
  • 17
    Mainolfi C, Maurea S, Varrella P, Alaia C, Imparato C, Alfano B, et al. Positron emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment. Radiol Med 1998;95: 98104.
  • 18
    Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19: 105563.
  • 19
    Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 7218.
  • 20
    Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 111722.
  • 21
    Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 42933.
  • 22
    Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999; 38: 799804.
  • 23
    Wiedmann E, Baican B, Hertel A, Baum RP, Chow KU, Knupp B, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma 1999; 34: 54551.
  • 24
    Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32: 68691.
  • 25
    Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. Positron emission tomography using fluorine-18-fluorodeoxy-glucose in malignant lymphoma; a comparison with proliferative activity. J Nucl Med 1992; 33: 3259.
  • 26
    Draisma A, Maffioli L, Gasparini M, Savelli G, Pauwels E, Bombardieri E. Gallium-67 as a tumor-seeking agent in lymphomas—a review. Tumori 1998; 84: 43441.
  • 27
    Som P, Atkins HL, Bandophadhyah D. A fluorinated glucose analog, 2-fluoro-2deoxy-D-glucose (F-18). J Nucl Med 1980; 21: 6705.
  • 28
    Gallamini A, Biggi A, Fruttero A, Pugno F, Cavallero G, Pregno P, et al. Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma. Eur J Nucl Med 1997; 24: 1499506.
  • 29
    Nejmeddine F, Caillat-Vigneron N, Escaig F, Moretti JL, Raphael M, Galle P. Mechanism involved in gallium-67 (Ga-67) uptake by human lymphoid cell lines. Cell Mol Biol 1998; 44: 121520.
  • 30
    Bekerman C, Hoffer PB, Bitran JD. The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med 1984; 14: 296323.
  • 31
    Kostakoglu L, Yeh SD, Portlock C, Heelan R, Yao TJ, Niedzwiecki D, et al. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992; 33: 34550.
  • 32
    Waxman AD, Eller D, Ashook G, Ramanna L, Brachman M, Heifetz L, et al. Comparison of gallium-67 citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma. J Nucl Med 1996; 37: 4650.
  • 33
    Aho R, Haapasalo H, Alanen K, Haltia M, Paetau A, Kalimo H. Proliferative activity and DNA index do not significantly predict survival in primary central nervous system lymphoma. J Neuropathl Exp Neurol 1995; 54: 82632.
  • 34
    Wellman A, Krenacs L, Fest T, Scherf U, Pastan I, Raffeld M, et al. Localization of the cell proliferation and apoptosis-associated CAS protein in lymphoid neoplasms. Am J Pathol 1997; 150: 2530.
  • 35
    Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36: 17906.
  • 36
    Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206: 47581.
  • 37
    Zimny M, Kaiser HJ, Cremerius U, Sabri O, Schreckenberger M, Reinartz P, et al. F-18-FDG positron imaging in oncological patients: gamma camera coincidence detection versus dedicated PET. Nuklearmedizin 1999; 38: 10814.